RESUMO
Although the use of methotrexate (MTX) is gaining acceptance in the treatment of several connective tissue diseases, there is little evidence of its therapeutic value in systemic lupus erythematosus (SLE). We examined the response to MTX in patients with steroid-resistant SLE in an open, unblinded study. Of 10 SLE patients treated with MTX (7.5 mg/weekly), 7 showed improvement. The other 3 stopped therapy because of lack of response or because of side effects. Improvements were noted within 3 months in responding patients. These promising observations suggest that controlled studies of MTX for the treatment of SLE are justified.
Assuntos
Lúpus Eritematoso Sistêmico/tratamento farmacológico , Metotrexato/uso terapêutico , Esteroides/uso terapêutico , Adolescente , Adulto , Ensaios Clínicos como Assunto , Resistência a Medicamentos , Gastroenteropatias/induzido quimicamente , Humanos , Lúpus Eritematoso Sistêmico/fisiopatologia , Metotrexato/efeitos adversos , Pessoa de Meia-Idade , Doenças da Boca/induzido quimicamente , Úlcera/induzido quimicamenteRESUMO
The authors found a significantly higher incidence of antinuclear antibodies (ANA) and positive lupus erythematosus cell tests in chronic psychotic patients who received 400 mg a day or more of chlorpromazine (CPZ) for at least 7 weeks than in those who had taken 50 to 300 mg a day for varying periods or those who had received no CPZ for at least 3 months. Despite the high incidence of ANA, there was no observed development of lupuslike syndrome. The authors suggest that CPZ in high doses may induce ANA in humans.
